1 / 9

Funding Update: Current Situation and Future Prospects

Funding Update: Current Situation and Future Prospects. September 18, 2012 Andrea Gay, UNF. MR Initiative Annual Expenditure, 2001-2012. Total expenditure 2001-2012 = $935 million. * Excluding country contributions.

tynice
Télécharger la présentation

Funding Update: Current Situation and Future Prospects

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Funding Update: Current Situation and Future Prospects September 18, 2012 Andrea Gay, UNF

  2. MR Initiative Annual Expenditure, 2001-2012 Total expenditure 2001-2012 = $935 million * Excluding country contributions

  3. Measles & Rubella Initiative Annual Donations 2001-2012 and Financial Resource Requirements, Projections, Funding Gap 2012-2015* 94 59 11 36 38 44 * Excludes all country contributions and direct social mobilization funding from partners

  4. Measles & Rubella Initiative Financial Resource Requirements, Projections, Funding Gap 2013-2015 47 Total Funding Gap 2013-2015: US $96 million 32 18 31 Anticipated Country Contributions Anticipated GAVI Contribution (Rubella) Donor Funds Projected/Pledged/Received Funding Gap (includes PSC)

  5. Resource Requirements by Major Category of Activity, 2013-2015 TotalCost 2013-2015: US $739 million

  6. MR Initiative Donors, 2001-2012 * Includes ARC/UNF and other partners

  7. Where is the Measles & Rubella Initiative Headed? • 2012 measles goals: AFRO (pre-elimination) and WPRO (elimination) • 2013 potential SEARO elimination goal set, begin MR introduction campaigns with GAVI support • 2015GIVS (95% mortality reduction) and MDG 4 goals; measles goal in EMRO and EURO (elimination); rubella goal in EURO (elimination) • 2020goal in AFRO (elimination) • Expand rubella introduction where appropriate; set goals Critical Elements for Success • Political leadership • Timely funding (donor and national governments) • Adequate time for planning and social mobilization • Well performing surveillance

  8. Measles and rubella elimination goalsby WHO Region, March 2012 2015 2015 2000 2010 2015 2012 2020 Pre-elim. (98%) 2012 SEAR: 95% Measles Mortality Reduction by 2015 Elimination 2020? Americas, Europe, E. Mediterranean, W. Pacific, Africa have measles elimination goals Americas and Europe have rubella elimination goals

  9. Considerations for Reorganizing Aspects of MR Initiative Operations • Measles eradication investment case (EIC): research, costing options • Strategic funding for regional elimination goals • Strategic support for non-GAVI eligible countries • Increased surveillance costs (including lab, coverage surveys) • Increased communications costs • Increased training costs for SIAs • Type of MR Initiative involvement (ex: T.A.) in GAVI funded MR intro SIAs or GAVI funded measles SIAs in 6 large countries • Outbreak response fund • Routine immunization • Scale up of MCV1 • Increase MCV2 introduction • Rubella & CRS (MR) • Follow-up campaigns

More Related